Thomas Gabrielczyk

3 weeks ago | european-biotechnology.com | Thomas Gabrielczyk

MoonLake Immunotherapeutics (Zug, Switzerland) AG’s debt agreement with Hercules Capital Inc. includes an US$75m payment at signature adding to  the company’s cash base of US$448m. Further debt tranches will be available upon achievement of pre-specified milestones. “We were able to secure deal terms, including a very sizeable commitment and a highly competitive cost of capital,” commented Matthias Bodenstedt, Chief Financial Officer at MoonLake Immunotherapeutics.

3 weeks ago | european-biotechnology.com | Thomas Gabrielczyk

The EU Commission’s bioeconomy strategy has to date centered on the utilisation of agricultural, forestry and industrial waste streams. However, a substantial raw material gap remains to be filled in order to fully transition from a fossil-based economy to bio-based solutions, as recently highlighted in presentations by the cabinet of the responsible Commissioner, Jessika Roswall.

3 weeks ago | european-biotechnology.com | Thomas Gabrielczyk

The new approach for equivalence testing of biosimilars, which is outlined in a new draft reflection paper, is designed to reduce the amount of clinical data required for the development and approval of biosimilar medicines. It builds on the 2024 Procedure for European Union guidelines and related documents within the pharmaceutical legislative framework‘. The EMA‘s consultation will end at the end of September and will be implemtented in 2026.

3 weeks ago | european-biotechnology.com | Thomas Gabrielczyk

“The applications have been reviewed and we are pleased to announce the 12 start-ups and emerging technology companies that have been selected for SLAS Europe 2025 Innovation AveNEW in Hamburg,” Jill Hronek, SLAS Director of Marketing and Communications, told European Biotechnology Magazine. SLAS will select up to ten finalists from the companies for the €5,000 SLAS Ignite Award, which recognises the most innovative start-up in the field of laboratory automation and drug screening.

4 weeks ago | european-biotechnology.com | Thomas Gabrielczyk

Recent studies have identified 4-hydroxyphenylpyruvate dioxygenase (HPPD), an enzyme of the tyrosine detoxification pathway, as essential for hematophagous arthropods such as Anopheles mosquitos to digest their blood meals.